10-Q: Femasys Inc. Reports Second Quarter 2024 Results, Highlights FemaSeed Commercialization and FemBloc Trial Progress

Femasys Inc. reported a net loss of $4.68 million for the second quarter of 2024, while progressing with the commercial launch of FemaSeed and the clinical trial for FemBloc.

Summary

• Femasys Inc. reported a net loss of $4.68 million for the three months ended June 30, 2024, and a net loss of $8.28 million for the six months ended June 30, 2024.
• Sales decreased to $221,484 for the quarter and $492,624 for the six months, primarily due to the timing of international sales.
• The company's operating expenses increased to $4.63 million for the quarter and $8.28 million for the six months, driven by higher research and development, sales and marketing, and general and administrative costs.
• The company completed enrollment in the FemaSeed pivotal trial and announced positive topline data, showing a 24% pregnancy rate with male factor infertility.
• Femasys received EU MDR and CE Mark certification for FemaSeed, FemVue, FemCerv, and FemCath.
• The company is progressing with the FINALE pivotal trial for FemBloc, with all six initial sites actively enrolling subjects.
• As of June 30, 2024, the company had cash and cash equivalents of $13.5 million.
• The company has raised approximately $8.7 million through an at-the-market offering and $6.3 million through a convertible note offering in November 2023.
• The company has an accumulated deficit of $116.67 million as of June 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in product development and regulatory approvals, the company's financial performance is weak, with increasing losses and a need for additional capital. The going concern warning is a significant negative factor.

Positives

• FemaSeed received FDA clearance and demonstrated a significantly higher pregnancy rate compared to traditional IUI in clinical trials.
• The company has obtained EU MDR and CE Mark certification for multiple products, expanding its market reach.
• The FINALE trial for FemBloc is progressing, with all initial sites actively enrolling subjects.
• Femasys has a strong intellectual property portfolio and in-house manufacturing capabilities.
• The company has secured additional financing through equity and debt offerings.

Negatives

• The company reported a net loss of $4.68 million for the quarter and $8.28 million for the six months ended June 30, 2024.
• Sales decreased by 30.9% for the quarter and 19.8% for the six months compared to the same periods in 2023.
• Operating expenses increased significantly, driven by higher R&D, sales and marketing, and general and administrative costs.
• The company has an accumulated deficit of $116.67 million as of June 30, 2024.
• The company's cash and cash equivalents are not sufficient to fund operations for the next twelve months.

Risks

• The company's ability to continue as a going concern is in doubt due to its current financial liquidity.
• The company needs to raise additional capital to fund the development and commercialization of FemBloc.
• There is no assurance that the company will be able to obtain additional financing on acceptable terms.
• The company may need to terminate, modify, or delay the development of its product candidates if it cannot secure additional funding.
• The company's operating losses are expected to increase over the next few years as it advances FemBloc through clinical development.
• The company's ability to achieve and maintain adequate levels of coverage or reimbursement for its products is uncertain.

Future Outlook

The company plans to finance its operations and development needs with existing cash, additional equity and/or debt financing, and revenue from the sale of FemVue and FemaSeed. The company expects losses to increase over the next few years as it advances FemBloc through clinical development. The company's current cash is sufficient into July 2025, but additional financing will be required to fund ongoing operations and the development of FemBloc.

Management Comments

• The company is focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions.
• The company's mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
• The company is a woman-founded and led company with an expansive, internally created intellectual property portfolio.
• The company has in-house chemistry, manufacturing, and controls (CMC) and device manufacturing capabilities and proven ability to develop and commercialize products.

Industry Context

Femasys operates in the women's health market, which includes infertility solutions and permanent birth control. The company's products and product candidates aim to provide minimally invasive, non-surgical alternatives to traditional methods. The company is competing with established players in the market, as well as other emerging companies developing innovative solutions in this space. The company's focus on in-office procedures and non-pharmaceutical solutions aligns with a growing trend towards patient convenience and reduced reliance on drugs and surgery.

Comparison to Industry Standards

• The 24% pregnancy rate achieved in the FemaSeed trial is significantly higher than the historical 6.7% rate for IUI with male factor infertility, suggesting a potential competitive advantage.
• The company's focus on non-surgical, non-implant, non-hormonal solutions for permanent birth control with FemBloc differentiates it from existing options like tubal ligation and Essure.
• The company's in-house manufacturing capabilities provide greater control over production and potentially lower costs compared to companies that rely solely on third-party manufacturers.
• The company's intellectual property portfolio of over 180 patents provides a strong competitive barrier against potential competitors.
• The company's financial results are typical of a development-stage medical device company, with significant operating losses and a need for additional capital to fund ongoing operations and clinical trials. Comparible companies include those in the early stages of clinical trials such as Daré Bioscience, Inc. and Evofem Biosciences, Inc.

Management Changes

Legal Proceedings

• As of June 30, 2024, there are no currently pending legal actions against the company.

Related Party Transactions

• In November 2023, the company issued a $5 million convertible note and warrants to PharmaCyte Biotech, Inc., where Joshua Silverman, a member of the company's board of directors, serves as interim CEO, President and Director.
• A family member of the CEO was employed by the company during the year ended December 31, 2023 and the six months ended June 30, 2024 and 2023.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment if the company is unable to secure additional financing.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers may benefit from the company's innovative products, but the availability of these products may be affected by the company's financial stability.
• Suppliers and creditors may face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• Continue commercial launch of FemaSeed in the United States.
• Explore potential strategic partners for distribution of FemaSeed in Europe and internationally.
• Continue enrollment in the FINALE pivotal trial for FemBloc.
• Conduct an interim analysis of clinical data endpoints for FemBloc once 300 women have used the product for one year.
• Seek additional financing to fund ongoing operations and the development of FemBloc.

Key Dates

Keywords

Femasys, FemaSeed, FemBloc, FemVue, infertility, birth control, clinical trial, FDA, EU MDR, CE Mark, biomedical, medical devices, women's health, financing, convertible notes, equity offering